TENAMYD PHARMACEUTICAL CORPORATION

TENAMYD PHARMACEUTICAL CORPORATION (CÔNG TY CỔ PHẦN DƯỢC PHẨM TENAMYD) is a privately held pharmaceutical manufacturer operating in Vietnam’s healthcare and life sciences sector. Established on 14 August 2007, TENAMYD PHARMACEUTICAL CORPORATION has built more than 18 years of operational history, focusing on the production of pharmaceuticals, medicinal chemicals, and botanical-based healthcare products.

Legal Status and Corporate Profile

TENAMYD PHARMACEUTICAL CORPORATION is registered under Business ID and Tax Identification Number 0305131303 with the Ho Chi Minh City Department of Finance. The company’s head office and main manufacturing facility are located at Lot Y.01–02A, Tan Thuan Street, Tan Thuan Industrial Park (Tan Thuan Export Processing Zone), Ho Chi Minh City, Vietnam. A warehouse facility is also maintained at Tan Tao Industrial Park, supporting storage and distribution activities.

The company operates as an active joint stock company with private ownership. It has a fully paid charter capital of approximately USD 7.39 million and employs around 320 staff, reflecting a medium-scale industrial pharmaceutical operation.

Core Operations and Business Scope

The principal activity of TENAMYD PHARMACEUTICAL CORPORATION is the manufacture of pharmaceuticals, including medicines, health supplements, and related healthcare products. In addition, the company produces cosmetics, personal care products, medical supplies, and health-related consumer goods. Its registered business scope also includes wholesale and retail distribution of pharmaceutical products, market research, advertising, logistics services, and technical testing.

This diversified registration enables the company to operate across multiple segments of the healthcare value chain, from manufacturing and quality control to marketing and distribution, supporting flexibility in product development and market expansion.

Management and Ownership

The company is managed by its General Director, Mr. BUI T. N., supported by a Deputy General Director. The management structure reflects a combination of international and local expertise, with leadership experience spanning both pharmaceutical manufacturing and commercial operations.

Ownership is concentrated among individual shareholders, primarily members of the founding shareholder group. While the shareholder list reflects historical data, equity control remains closely held, enabling streamlined governance and long-term strategic consistency.

Financial Performance and Trends

Financially, TENAMYD PHARMACEUTICAL CORPORATION demonstrates improving operational efficiency and profitability. Total assets declined slightly in the most recent period, indicating balance-sheet optimization rather than contraction. Sales revenue continued to grow steadily, reflecting stable demand for pharmaceutical and healthcare products.

Profitability increased strongly, with net profit rising sharply year-on-year. Equity also expanded, supported by retained earnings, while working capital improved significantly, strengthening short-term liquidity and operational flexibility. This financial profile suggests effective cost management, improved margins, and disciplined capital utilization.

Overall, the company presents a solid mid-sized pharmaceutical profile with stable revenue growth and accelerating profitability.

Business Outlook and Risk Considerations

Operating in the pharmaceutical sector exposes TENAMYD PHARMACEUTICAL CORPORATION to regulatory compliance requirements, quality assurance standards, pricing controls, and competition from both domestic and international manufacturers. However, the company’s established production base, diversified product portfolio, and improving financial metrics provide resilience against sector-specific risks.

For banks, insurers, distributors, and business partners, attention should focus on regulatory compliance, product quality systems, and sustainability of profit growth. A comprehensive and up-to-date company report is essential for evaluating credit risk, ownership structure, and long-term operational viability.